Tags

Type your tag names separated by a space and hit enter

Anastrozole for breast cancer: recent advances and ongoing challenges.
Expert Rev Anticancer Ther. 2006 Jun; 6(6):839-48.ER

Abstract

Third-generation aromatase inhibitors are accepted widely as alternatives to tamoxifen for the treatment of advanced breast cancer in postmenopausal women and, currently, are increasingly replacing tamoxifen in the adjuvant setting. This drug profile focuses on recent clinical developments in the use of anastrozole and, in particular, on the Arimidex, Tamoxifen, Alone or in Combination trial, which has shown that initial adjuvant treatment with anastrozole has significant efficacy and tolerability advantages compared with tamoxifen for postmenopausal women with early breast cancer. Results of adjuvant switching, extended adjuvant and preoperative (neoadjuvant) studies are reviewed and the potential of anastrozole in a range of clinical settings is discussed. Treatment recommendations and the future role of anastrozole in the management of patients with early breast cancer are also considered.

Authors+Show Affiliations

Buzdar AU
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030-4009, USA. abuzdar@mdanderson.org

MeSH

AnastrozoleAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantFemaleHumansNitrilesTamoxifenTriazoles

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16761927

Citation

Buzdar, Aman U.. "Anastrozole for Breast Cancer: Recent Advances and Ongoing Challenges." Expert Review of Anticancer Therapy, vol. 6, no. 6, 2006, pp. 839-48.
Buzdar AU. Anastrozole for breast cancer: recent advances and ongoing challenges. Expert Rev Anticancer Ther. 2006;6(6):839-48.
Buzdar, A. U. (2006). Anastrozole for breast cancer: recent advances and ongoing challenges. Expert Review of Anticancer Therapy, 6(6), 839-48.
Buzdar AU. Anastrozole for Breast Cancer: Recent Advances and Ongoing Challenges. Expert Rev Anticancer Ther. 2006;6(6):839-48. PubMed PMID: 16761927.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anastrozole for breast cancer: recent advances and ongoing challenges. A1 - Buzdar,Aman U, PY - 2006/6/10/pubmed PY - 2006/6/21/medline PY - 2006/6/10/entrez SP - 839 EP - 48 JF - Expert review of anticancer therapy JO - Expert Rev Anticancer Ther VL - 6 IS - 6 N2 - Third-generation aromatase inhibitors are accepted widely as alternatives to tamoxifen for the treatment of advanced breast cancer in postmenopausal women and, currently, are increasingly replacing tamoxifen in the adjuvant setting. This drug profile focuses on recent clinical developments in the use of anastrozole and, in particular, on the Arimidex, Tamoxifen, Alone or in Combination trial, which has shown that initial adjuvant treatment with anastrozole has significant efficacy and tolerability advantages compared with tamoxifen for postmenopausal women with early breast cancer. Results of adjuvant switching, extended adjuvant and preoperative (neoadjuvant) studies are reviewed and the potential of anastrozole in a range of clinical settings is discussed. Treatment recommendations and the future role of anastrozole in the management of patients with early breast cancer are also considered. SN - 1744-8328 UR - https://www.unboundmedicine.com/medline/citation/16761927/Anastrozole_for_breast_cancer:_recent_advances_and_ongoing_challenges_ DB - PRIME DP - Unbound Medicine ER -